Patents matching “formulation”

CA 2760177

FORMULATION ALIMENTAIRE COMPRENANT DU GLYCOGENE

ACRAF [IT] · Granted Feb 10, 2011 · Expires Feb 5, 2031

US 7855176

Reduced volume formulation of glatiramer acetate and methods of administration

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Dec 21, 2010 · Expires Dec 16, 2030

US 7829533

Cyclosporin analog formulations

Isotechnika, Inc. · Granted Nov 9, 2010 · Expires Nov 4, 2030

US 2010273803

Oral Formulations for Tetrapyrrole Derivatives

CERAMOPTEC IND INC [DE] · Granted Oct 28, 2010 · Expires Oct 23, 2030

US 7815935

Orally distintegrating formulation and process for preparing the same

Quantum Hi-Tech (Beijing) Research Institute · Granted Oct 19, 2010 · Expires Oct 14, 2030

US 7815942

Rasagiline formulations of improved content uniformity

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Oct 19, 2010 · Expires Oct 14, 2030

US 7811602

Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof

Tekmira Pharmaceuticals Corporation · Granted Oct 12, 2010 · Expires Oct 7, 2030

US 7807164

Lyophilized VEGF antagonist formulations for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Oct 5, 2010 · Expires Sep 30, 2030

US 7771707

Abuse-deterrent drug formulations

Collegium Pharmaceutical, Inc. · Granted Aug 10, 2010 · Expires Aug 5, 2030

US 7759359

Method of treating bladder dysfunction with once-a-day trospium salt formulation

Supernus Pharmaceuticals, Inc. · Granted Jul 20, 2010 · Expires Jul 15, 2030

US 7749532

Once daily formulations of tetracyclines

Supernus Pharmaceuticals, Inc. · Granted Jul 6, 2010 · Expires Jul 1, 2030

US 7749536

Pharmaceutical formulations of aliphatic amine polymers and methods for their manufacture

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Jul 6, 2010 · Expires Jul 1, 2030

US 7678828

Methods for the formulation and manufacture of artesunic acid for injection

The United States of America as represented by the Secretary of the Army · Granted Mar 16, 2010 · Expires Mar 11, 2030

US 7678764

Protein formulations for use at elevated temperatures

JOHNSON & JOHNSON REGENERATIVE THERAPEUTICS, LLC · Granted Mar 16, 2010 · Expires Mar 11, 2030

US 7655758

Stable liquid IL-1 antagonist formulations

REGENERON PHARMACEUTICALS, INC. · Granted Feb 2, 2010 · Expires Jan 28, 2030

CA 2765866

FORMULATION PHARMACEUTIQUE

ALPHAPHARM PTY LTD [AU] · Granted Dec 23, 2009 · Expires Dec 18, 2029

US 7629005

Pharmaceutical formulation consisting of a plant dry extract with a calcium coating

Bionorica AG · Granted Dec 8, 2009 · Expires Dec 3, 2029

US 7619117

Rasagiline formulations and processes for their preparation

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Nov 17, 2009 · Expires Nov 12, 2029

US 7608261

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Oct 27, 2009 · Expires Oct 22, 2029

US 7598420

Rasagiline formulations and processes for their preparation

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Oct 6, 2009 · Expires Oct 1, 2029

US 7582312

Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof

Discovery Laboratories, Inc. · Granted Sep 1, 2009 · Expires Aug 27, 2029

US 7572893

IL-1 antagonist formulations

REGENERON PHARMACEUTICALS, INC. · Granted Aug 11, 2009 · Expires Aug 6, 2029

US 7572834

Rasagiline formulations and processes for their preparation

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Aug 11, 2009 · Expires Aug 6, 2029

US 7566462

Stable tablet formulation

BIOMARIN PHARMACEUTICAL INC. · Granted Jul 28, 2009 · Expires Jul 23, 2029